Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bios.2021.113406 http://scihub22266oqcxt.onion/10.1016/j.bios.2021.113406 34167074!8178056!34167074     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biosens+Bioelectron 2021 ; 191 (ä): 113406 Nephropedia Template TP {{tp|p=34167074|t=2021. A rapid quantitative on-site coronavirus disease 19 serological test |pdf=|usr=}}{{34167074}} gab.com Text A rapid quantitative on-site coronavirus disease 19 serological test JO: Biosens Bioelectron http://www.kidney.de/pget.php?&tw=1&pmid=34167074 #FOAvip On-site severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) serological assays allow for timely in-field decisions to be made regarding patient status, also enabling population-wide screening to assist in controlling the coronavirus disease 2019 (COVID-19) pandemic. Here we propose a rapid microfluidic serological assay with two unique functions of nanointerstice filling and digitized flow control, which enable the fast/robust filling of the sample fluid as well as precise regulation of duration and volume of immune reaction. Developed microfluidic assay showed enhanced limit of detection, and 91.67% sensitivity and 100% specificity (n = 152) for clinical samples of SARS CoV-2 patients. The assay enables daily monitoring of IgM/IgG titers and patterns, which could be crucial parameters for convalescence from COVID-19 and provide important insight into how the immune system responds to SARS CoV-2. The developed on-site microfluidic assay presented the mean time for IgM and IgG seroconversions, indicating that these titers plateaued days after seroconversion. The mean duration from day 0 to PCR negativity was 19.4 days (median 20 d, IQR 16-21 d), with higher IgM/IgG titres being observed when PCR positive turns into negative. Simple monitoring of these titres promotes rapid on-site detection and comprehensive understanding of the immune response of COVID-19 patients. Twit Text FOAVip A rapid quantitative on-site coronavirus disease 19 serological test ????Biosens Bioelectron http://www.kidney.de/pget.php?&tw=1&pmid=34167074 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34167074 #FOAvip English Wikipedia <ref>{{Cite pmid|34167074}}</ref> A rapid quantitative on-site coronavirus disease 19 serological test #MMPMID34167074 Lee JH; Bae PK; Kim H; Song YJ; Yi SY; Kwon J; Seo JS; Lee JM; Jo HS; Park SM; Park HS; Shin KS; Chung S; Shin YB Biosens Bioelectron 2021[Nov]; 191 (ä): 113406 PMID34167074show ga On-site severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) serological assays allow for timely in-field decisions to be made regarding patient status, also enabling population-wide screening to assist in controlling the coronavirus disease 2019 (COVID-19) pandemic. Here we propose a rapid microfluidic serological assay with two unique functions of nanointerstice filling and digitized flow control, which enable the fast/robust filling of the sample fluid as well as precise regulation of duration and volume of immune reaction. Developed microfluidic assay showed enhanced limit of detection, and 91.67% sensitivity and 100% specificity (n = 152) for clinical samples of SARS CoV-2 patients. The assay enables daily monitoring of IgM/IgG titers and patterns, which could be crucial parameters for convalescence from COVID-19 and provide important insight into how the immune system responds to SARS CoV-2. The developed on-site microfluidic assay presented the mean time for IgM and IgG seroconversions, indicating that these titers plateaued days after seroconversion. The mean duration from day 0 to PCR negativity was 19.4 days (median 20 d, IQR 16-21 d), with higher IgM/IgG titres being observed when PCR positive turns into negative. Simple monitoring of these titres promotes rapid on-site detection and comprehensive understanding of the immune response of COVID-19 patients. |*Biosensing Techniques[MESH] |*COVID-19[MESH] |Antibodies, Viral[MESH] |Humans[MESH] |Immunoassay[MESH] |Immunoglobulin G[MESH] |Immunoglobulin M[MESH] |SARS-CoV-2[MESH] |Sensitivity and Specificity[MESH]A rapid quantitative on-site coronavirus disease 19 serological test (epmc).pdf DeepDyve Pubget Overpricing